ERBB2 and breast cancer: Among patients with HER2− BC, anti-tumor immune cells, such as CD8+ T cells and resting dendritic cells, were obviously downregulated in the high-risk group, while cancer-promoting cells, such as CD4+ T memory resting cells, were upregulated in the low-risk group (Supplementary Figure S6).